Understanding Receptor Tyrosine Kinases to Define New Therapeutic Opportunities

Dr. Lemmon is hosted by Dr. Daniel Leahy. Dr. Lemmon’s lecture, “Understanding Receptor Tyrosine Kinases to Define New Therapeutic Opportunities,” will be begin at 4 p.m. in POB 2.302 with a reception to follow at 5 p.m.

Mark Lemmon is the Alfred Gilman Professor and Chair of Pharmacology at Yale School of Medicine. Lemmon’s research focuses on understanding the signaling networks controlled by receptor tyrosine kinase (RTK) growth factors that, when mutated, cause cancers and other diseases. His laboratory combines biochemical, structural, biophysical and cellular approaches to investigate how these networks function, and also collaborates with clinical groups to apply the mechanistic lessons learned to inhibitor choice and combating development of resistance to targeted therapies in the clinic.